Bifidobacterium breve MAK40B22B and Enhanced Immunogenicity of Cholera Vaccine

• Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: a randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age.

  • 2011-02-24
  • RCT
  • Vaccine 29(10)
  • • F. Matsuda
    • M. Chowdhury
    • A. Saha
    • T. Asahara
    • K. Nomoto
    • A. Tarique
    • T. Ahmed
    • M. Nishibuchi
    • A. Cravioto
    • F. Qadri

  • PubMed: 21236234
  • DOI: 10.1016/j.vaccine.2010.12.133

  13 Insights on

  • Enhanced Immunogenicity of Cholera Vaccine

  • High evidence

  Immunological responses were similar comparing the two groups.

  Effect

  Neutral

  Effect size

  Small

  Significant

  No